We tested the usefulness of epidermal growth factor receptor (EGFR) 
We tested the usefulness of epidermal growth factor receptor (EGFR) immunostaining in primary colorectal adenocarcinoma as a predictor for EGFR status of tumor recurrences in 33 primary tumors and distant recurrences (July 1994 to June 2005). Representative primary and recurrent tumor sections were stained using mouse anti-EGFR antibodies, and only membranous staining of malignant cells was recorded. Results were reported as negative (no staining), 1+ (positivity in <50% of cells), or 2+ (positivity in >50% of cells). Of 33 cases, 19 (58%) showed the same extent of immunopositivity in primary and recurrent tumors. Bivariate logistic regression analysis of primary tumors with 2+ vs those with negative or 1+ staining showed that the primary tumor status had a major predictive relationship with that of recurrence (odds ratio, 45.99; confidence limit, 4.0-524.9; P = .0021). The difference between the median time to recurrence of primary tumors with the various degrees of staining was not statistically significant. Our reporting method provides a useful correlation between the staining profiles of primary colorectal adenocarcinoma and recurrent disease. It is exceptionally reliable in predicting immunopositivity of a recurrence when more than 50% of cells of the primary tumor are immunoreactive.
During the last several years, the systemic treatment of colorectal cancer has become a rapidly evolving field. For many years, the backbone of therapy was 5-fluorouracil, a cytotoxic drug. In recent years, a variety of new agents have become available. 1 Among these, "targeted" biologic therapies have generated considerable promise. One therapeutic target is the epidermal growth factor receptor (EGFR), which is overexpressed in approximately 70% to 75% of colorectal cancers as determined by immunohistochemical analysis. 2 EGFR is a transmembrane glycoprotein consisting of an extracellular ligand-binding domain, a transmembrane region, and an intracellular tyrosine kinase domain. 3, 4 It is a rational target for therapy because deregulation of its signaling pathways has been linked to tumor proliferation, invasion, cellular migration, angiogenesis, and resistance to apoptosis. 5 Cetuximab (Erbitux) is a human-murine chimeric antibody (IgG1) that targets the extracellular domain of EGFR with high specificity and affinity. 6 Clinical trials in the setting of metastatic colon cancer refractory to chemotherapy have shown efficacy with modest toxic effects when the drug is used as a single agent and in combination with irinotecan. [7] [8] [9] In current clinical practice, cetuximab is used as second-or third-line systemic therapy for metastatic colorectal cancer.
Given the modest efficacy and significant cost of cetuximab, there is a need to better identify the patients who would benefit from the agent. However, controversy exists about which patients should be treated with cetuximab. Initial studies included only patients with immunohistochemical evidence of EGFR expression in mostly primary tumor samples rather than in recurrent tumors. It was noted, however, that the degree of expression seemed unrelated to the likelihood of response, 9 which raised questions about whether cetuximab could be interacting with other molecular targets and whether receptor overexpression should be a prerequisite for cetuximab treatment. A recent report of 16 cases of metastatic colorectal cancer treated with cetuximab that were EGFR-negative by immunohistochemical analysis showed response rates similar to those seen in the clinical trials involving patients with positive EGFR immunohistochemical results. 10 The apparent discordance between immunohistochemical detection of EGFR expression and clinical response to anti-EGFR treatment has several possible explanations, including variability in EGFR staining techniques and interpretation, antigen loss due to processing, biologic changes in the tumor, and the possibility that the treatment might work through pathways other than EGFR. 10 In the majority of studies, EGFR immunohistochemical analysis was performed on archival tissue specimens from the primary tumor that was removed before any chemotherapy. Cetuximab is given to patients with metastatic disease after failure of initial systemic treatment. Given that the metastatic, posttreatment tumor may be biologically distinct from the primary tumor, the assumption that a distant recurrence will maintain the same EGFR status as its primary might not be correct. Previous studies in other solid tumors have demonstrated differences in EGFR expression between primary tumors and metastases. 11 The purpose of our study, therefore, was to determine the degree of concordance between EGFR expression in primary and recurrent colorectal cancers using immunohistochemical staining of tumors from patients who had both tumors resected at our institution.
Materials and Methods

Specimen Selection
From the pathology files, we retrieved 33 cases of colorectal adenocarcinoma, not otherwise specified, in which distant recurrence of the tumors developed and patients had both their primary and recurrent tumors resected at our institution. The cases were accessioned during the period of July 1994 to June 2005. All patients underwent surgical resection of the primary tumors. Later, liver segmentectomy or lobectomy was performed in 31 cases and lung lobectomy in 2 cases to resect recurrences. An experienced gastrointestinal pathologist (M.A.K.) reviewed all H&E-stained slides from the resected primary and recurrent tumors to confirm the diagnosis and to select a block for immunohistochemical staining.
Immunohistochemical Staining
Immunostaining was performed on 5-µm-thick, formalin-fixed, paraffin-embedded tissue sections using a DAKO Autostainer (DAKO, Carpinteria, CA) according to the manufacturer's specifications. Sections were stained using mouse anti-EGFR antibodies (Zymed Laboratories, San Francisco, CA). The antibody used was clone 31G7, and sections were incubated for 30 minutes at room temperature at a dilution of 1:100. Predigestion by pepsin at 37°C for 10 minutes was performed. Positive (ductal carcinoma of the breast) and negative control samples were stained with every run. To avoid potential interference by endogenous biotin in liver tissue, the biotin-free detection system, mouse-probe horseradish peroxidase polymer kit (MACH 3, Biocare Medical, Walnut Creek, CA) was used. Sections were immunostained in batches and processed by 1 experienced immunohistotechnologist.
Evaluation and Analysis
Positive staining was defined as any membranous brown staining of malignant cells above the background level ❚Image 1❚ and ❚Image 2❚. Cytoplasmic staining without associated membrane staining was considered negative. The immunostaining results were recorded on a 3-tiered scale: negative, no staining; 1+, positivity in fewer than 50% of cells; and 2+, positivity in more than 50% of cells. To augment the objectivity of our results, the intensity of staining was not included as a reportable variable. Immunostaining of each of the primary and recurrent tumors was assessed blindly, without knowledge of the immunostaining status of its counterpart. The clinical and follow-up data were obtained from the patient's electronic charts. SAS 8.2 software (SAS Institute, Cary, NC) was used for data analysis.
❚Image 1❚ Epidermal growth factor receptor immunopositivity in <50% of cells in a colorectal adenocarcinoma metastatic to the liver (original magnification ×200).
Results
At the time of primary diagnosis, the patients (20 men and 13 women) ranged in age from 41 to 80 years (mean ± SD, 65.4 ± 10.2 years). Clinical data are summarized in ❚Table 1❚. None of the patients had received EGFR-targeted therapy.
As shown in ❚Table 2❚, 21 (64%) of the primary tumors and 17 (52%) of the recurrences had positive EGFR immunostaining. Of the 33 cases, 19 (58%) showed the same degree of immunopositivity in primary and recurrent tumors. We assessed conformity of the two types of lesions: the weighted κ statistics produced a value of 0.44, representing a moderate degree of agreement.
Because the proposed new therapies theoretically target immunopositive cells and to increase specificity of the testing process, the following statistical analysis focused on measuring the significance of immunostaining when the majority of cells were positive (2+) compared with cases with less or no staining (negative and 1+ staining combined). As shown in ❚Table 3❚, 29 primary tumors (88%) did not differ in their EGFR status at recurrence. Among the cases with disagreement, 3 primary tumors had 2+ staining and the recurrent tumors had negative or 1+ staining; only 1 case showed the reverse pattern. Although it seemed that the conversion of a tumor from more staining in the primary tumor to no or less staining in the recurrent tumor is the most likely pattern of disagreement, the McNemar test showed that the conversion in this direction was not statistically significant. Bivariate logistic regression analysis showed that the status of the primary tumor was significantly related to that of the recurrence with an odds ratio of 45.99 (confidence limit, 4.0-524.9; P = .0021.
Distant recurrence occurred 1 to 59 months (mean ± SD, 14.9 ± 10.3 months) after initial tumor resection ❚Table 4❚. The difference between the median time to recurrence of primary tumors with the various degrees of staining was not statistically significant (log-rank and Wilcoxon tests).
Anatomic Pathology / ORIGINAL ARTICLE ❚Image 2❚ Epidermal growth factor receptor immunopositivity in >50% of cells in a primary colorectal adenocarcinoma (original magnification ×200). 
Discussion
We assessed the EGFR status of paired primary and recurrent metastatic colorectal adenocarcinomas and reported the results on a 3-tiered scale (negative, no staining; 1+, positivity in <50% of cells; and 2+, positivity in >50% of cells). Of 33 recurrences, 19 (58%) showed the exact degree of EGFR immunostaining as that observed in the corresponding primary tumors, exhibiting a moderate degree of agreement (κ value, 0.44). Our results are similar to those reported recently by Italiano et al, 12 who found concordance between the paired primary colorectal tumors and distant metastatic lesions in 94% of samples. Further analysis of our primary tumors with EGFR positivity in more than 50% of cells (2+) compared with those with less or no staining (1+ and negative) showed that 29 primary tumors (88%) status was not altered when they recurred. This reporting method shows that the status of the primary tumor has a statistically significant predictive relationship with that of the recurrence (odds ratio, 44.99; confidence limit, 4.0-524.9; P = .0021).
A recent study concluded that EGFR status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites. 13 The study design and reporting system were different from ours. More than half of their patients had synchronous metastases, whereas all of our patients had metachronous metastases with recurrences occurring 1 to 59 months (mean ± SD, 14.9 ± 10.3 months) after initial tumor resection. Scartozzi et al 13 performed the statistical analysis of their immunostains reported on a 2-tiered system (negative, any membranous staining in <1% of cells; positive, membranous staining in ≥1%). We believe that setting the cutoff point at 1% or more creates an unnecessarily wide range of immunopositivity that probably contributed to the discrepant conclusions. We recognize that a 50% landmark also is arbitrary, but it is an objective measure that pathologists can follow with a reliable degree of concordance. Our proposed scheme shows a moderate degree of agreement between the status of the primary tumor and that of its recurrence. It also allows for a statistically significant prediction of the status of the recurrent tumor when more than half of the malignant cells of the primary tumor on the section examined are EGFR-positive.
Our study design excluded the intensity of staining from the analysis. The authors of 2 previous studies of EGFR expression in colorectal carcinoma 12, 13 reported the intensity of staining as weak, moderate, and strong. However, the statistical analysis of data in both studies focused on the overall status of cases according to the percentage of positive cells irrespective of staining intensity. The introduction of targeted biologic therapies to common tumors and the delicate refinement of the process of pathologic reporting to better select patients who likely will benefit is an evolving process. We believe that including the intensity of EGFR staining at this point will add too much subjectivity to this process.
The 14 Accordingly, we elected to use the antibody manufactured by Zymed Laboratories in the present study because this was the antibody used in our local laboratory for the past 3 years.
The US Food and Drug Administration approved cetuximab in February 2004, for use in patients with metastatic colorectal cancer refractory to irinotecan. It is given as third-line therapy as weekly therapy in combination with irinotecan or as monotherapy for patients unable to tolerate irinotecan. Studies in patients with EGFR-expressing tumors demonstrated a superior response rate and time to progression in patients who received cetuximab, although no overall survival advantage was observed. 9 In these studies, EGFR status was determined mostly by immunohistochemical staining of primary tumor samples rather than of recurrent or metastatic tumor samples. [7] [8] [9] The potential changes in the tumor's EGFR status spontaneously or due to postoperative chemotherapy effects were not addressed. The present study, along with the recent works of others, 12,13 resolves the concordance issue in an attempt to provide more solid grounds for patient selection without having to test the metastatic or recurrent tumors.
There is some evidence that EGFR expression has prognostic value in patients with colorectal cancer. [15] [16] [17] Metastatic colorectal cancer cells have been shown to have a 5-fold increase in EGFR messenger RNA compared with cells with low metastatic potential. 17 In 1 study, patients with colorectal cancer with fewer than 50% EGFR-positive cells had better overall survival than patients with tumors with increased EGFR expression. 16 Our study examined the relationship between the time to recurrence and the various degrees of EGFR immunopositivity. The median time to recurrence for cases with no immunostaining or immunostaining in fewer than 50% of cells (13 and 14 months, respectively) was slightly longer than that for patients with immunopositivity in more than 50% (12 months), although this difference was not statistically significant. However, there is evidence from the present study and from previous studies to support the prognostic relevance of EGFR expression in colorectal adenocarcinoma. The biology of EGFR in colorectal adenocarcinoma was reviewed recently. 18 EGFR is a receptor tyrosine kinase encoded by the c-erbB proto-oncogene. It is activated by ligands, including epidermal growth factor, transforming growth factor α, amphiregulin, heparin-binding epidermal growth factor, poxvirus mitogens, and betacellulin. Ligand-binding results in dimerization of 2 erbB receptor family members, allowing dimer autophosphorylation. This leads to activation of kinasemediated signaling pathways, which leads to recruitment of transcription factors in the cell nucleus, ultimately resulting in cell cycle progression, resistance to apoptosis, angiogenesis, invasion, and migration. Our study focused solely on overexpression of EGFR as assessed by immunohistochemical analysis. However, other mechanisms such as overexpression of ligands, autocrine or paracrine loops, or aberrant downstream signaling might have a role in colorectal cancer, precluding the demonstration of a direct relationship between EGFR immunostaining and tumor outcome.
The proposed reporting scheme in the present study showed that 58% of recurrences of colorectal adenocarcinomas will exhibit the same EGFR staining status as the primary tumors. In cases in which more than half of the neoplastic cells in the primary tumor are positive, the recurrent tumor is very likely to express similar EGFR immunopositivity. 
